



CIN No. : U24239DL2004PLC125888

## AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2024-25/09

August 24, 2024

**To,  
The Listing Department  
National Stock Exchange of India Ltd  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051**

**To,  
The Listing Department  
BSE Limited  
Rotunda Building, Phiroze  
Jeejeebhoy Towers, Dalal Street,  
Fort, Mumbai – 400 001**

**Symbol: AKUMS**

**Scrip Code: 544222**

**Sub: Press Release**

Respected Sir/Madam,


Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of press release is enclosed herewith.

This is for your kind information and record.

Thanking You

**For Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik  
Company Secretary & Compliance Officer



ISO 9001 : 2015  
ISO 14001 : 2015  
ISO 17025 : 2005 (NABL)

WHO-GMP  
US : NSF  
H A C C P



# Akums Drugs and Pharmaceuticals Limited Announces robust Q1 FY 25 results with 21% Adj EBITDA Growth and 52% Adj PAT growth

**Delhi: 24<sup>th</sup> August, 2024:** Akums Drugs and Pharmaceuticals Limited (BSE: 544222, NSE: AKUMS), the largest India focused CDMO with a market share of over 30% in domestic CDMO market serving 26 of the leading 30 pharmaceutical companies in India. It has a manufacturing capacity of 49.59 billion units annually spread across 60+ dosage forms. It owns 12 formulation manufacturing units along with 3 API units with accreditations such as EU-GMP, US NSF, WHO – GMP among others announced its unaudited consolidated financial results for the quarter ending June 30<sup>th</sup>, 2024.

## Financial Highlights

- Adj EBITDA margins grew by 21.1% YOY to 12.7%.
- Adj PAT margin improved to 5.6% with 52.1% YOY growth.
- Consolidated revenue grew to Rs 10,191 million, an increase of by 5.1% YOY.
- CDMO EBITDA margins improved by 106 bps YOY to 15.5%.
- Net debt reduced by over Rs 2,000 million to Rs 2,128 million YOY.

## Quarterly performance

The company's CDMO segment which accounts for 77% of total revenue and 93% of the Adj EBITDA, grew to Rs 7,820 million an increase of 5.6% yoy. This was driven by strong growth in sales volume of 13.9%. Segment EBITDA also saw margin expansion of 106 bps to 15.5%, growing 13.4% YoY to Rs 1,212 million on the back of steady improvement in capacity utilization and better product mix.

Branded and Generic Formulations segment more than doubled its EBITDA YOY, growing to Rs 171 million from Rs 74 million. This was driven by improved margins of branded domestic and exports business and curtailed losses in trade generics business.

The API segment saw revenue improvement of 82.6%, while segment EBITDA margins improved to -17.4% from -23.0% in Q1 FY 24 as the company continues to strive to achieve break even in this segment.

Debt to Equity improved to 0.25 times with Net debt at Rs 2,128 million.

Commenting on the financial performance, Mr. Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., stated, "Our Q1 results show our ongoing efforts to optimize our operations and capitalise on our strengths in the CDMO segment. We are committed to driving sustainable growth across all our business segments and delivering value to our stakeholders."

The new Injectable Facility housed in Akums Healthcare Ltd started commercial production on 22<sup>nd</sup> August 2024, with a capacity of 362 million units annually. Akums already has a significant presence in injectable CDMO space and this new facility is expected to consolidate its leadership position in Indian CDMO market.

Further, the board of directors, approved a plan to set up two production facilities in Jammu at an overall investment of Rs 2,650 million. These will be multi-dosage facilities across pharmaceutical and nutraceutical products.

Speaking on the company's plans, Mr. Sandeep Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., said, "The launch of our injectable facility and the Jammu expansion are key steps in our strategy to enhance our production capabilities. These developments, coupled with our ongoing efforts in R&D and innovation, are aligned with our endeavor to respond effectively to the evolving demands of our clients and the healthcare industry."

**For more information, contact:**

**Mr Dharamvir Malik**

**Email:** [dharamvir.malik@akums.net](mailto:dharamvir.malik@akums.net)

**Mr Ankit Jain**

**Email:** [ankit.jain@akums.net](mailto:ankit.jain@akums.net)

#### **Disclaimer**

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Akums Drugs and Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

#### **Definitions**

- Adjusted EBITDA has been calculated as the sum of profit/ (loss) for the quarter, tax expenses, finance costs, depreciation and amortization expense, fair value changes to financial instruments, share of profit/ (loss) of associates and exceptional items.
- Segment EBITDA is calculated as the sum of profit/ (loss) before tax, exceptional items, finance costs, fair value changes to financial instruments and depreciation and amortisation expense pertaining to respective segment.
- Adjusted PAT is calculated as the profit for the quarter plus fair value changes to financial instruments.
- CDMO: Contract Development and Manufacturing Operations
- API: Active Pharmaceutical Ingredients

#### **Details of Earnings Call:**

- **Date:** Friday, August 30<sup>th</sup>, 2024
- **Time:** 4:00 pm (IST)
- **Dial-In Numbers:**
  - Universal Access: +91 22 6280 1148 / +91 22 7115 8049
  - USA: 1 866 746 2133
  - UK: 0 808 101 1573
  - Singapore: 800 101 2045
  - Hong Kong: 800 964 448